Articles On Biotron (ASX:BIT)

As global markets move cautiously around the spreading Wuhan coronavirus, the ASX managed to recoup a small portion of yesterday’s losses with some tepid gains. The ASX 200 couldn’t get back Wednesday’s all-time highs but managed to add...

Biotech researcher Biotron (BIT) has been in the spotlight this week for a potential coronavirus cure Eagle-eyed investors noticed a late-December U.S. patent application mentioned specific treatments for the virus The company’s shares jum...

Stocks retreated from record highs as strong jobs growth undermined the case for further rate cuts. The ASX 200 fell 41 points or 0.6 per cent to 7092 by mid-session, erasing almost two-thirds of yesterday’s 66-point surge. Early los...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Board member Robert Thomas purchased one million shares in the company yesterday and shares finished up 40%.

Cancer is a crowded market, pot has sleep and pain issues covered — or so they say — and companies dip in and out of respiratory diseases all the time. But there are a few ASX-listed stocks that are tackling health issues that still rate as...

Drug development is an extensive process and includes drug discovery & development, pre-clinical and clinical research and FDA approvals, including Post-Market Drug Safety Monitoring. The first and the most essential step of drug devel...

Biotron Limited (ASX: BIT) would be presenting its latest clinical trial data at the Conference on Retroviral and Opportunistic Infections (‘CROI’), to be held in Boston MA, USA in March 2020. Ever since the company completed the BIT225-009...

Biotron (ASX BIT) has announced it has entered an Option Underwriting Agreement with Gleneagle Securities.

Drug Development Process The drug development process starts from drug discovery and ends at the launch of the new pharmaceutical product in the market. The process includes drug discovery and development, preclinical trials, clinical trial...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

In Australia, there are plenty of high-quality health care companies, most of which have delivered excellent returns. Investment in health care stocks is high yielding; however, it does include risks. If undergoing clinical studies fail to...

Australian Health Care is a dynamic sector with a potential to generate significant profits in the least amount of time, something, what investors eye for, while pouring cash in Stocks. In this article we will be digging into four Health Ca...

The Australian benchmark index S&P/ASX200 was trading at 6,499.1, up by 0.09 per cent (as on 4 October 2019, AEST 12:20 PM). In this article, we would discuss four diversified stocks wherein, Great Boulder Resources Limited is from the...

On 1 October 2005, I was only 20 metres away from a large bomb that went off in the heart of Kuta. The 2005 Bali bombings were a series of terrorist attacks across two sites in Jimbaran Bay and in Kuta - 30km away from each other, both in s...

Resources companies have come out on top in ASX small caps over the past 12 months – but now only account for just over 40 per cent of the 100 best performers in the 2019 financial year. Stockhead has compiled a list (see below) of the top...

Australia has a robust health care system, jointly operated by the federal, state and local governments, and is labeled as one of the best in the world. For investors, health care stands among the top few sectors, and is the safest sectors...

Holding huge growth potential, small cap stocks are those companies that are often under-recognised and have a small market capitalisation. Strategies like strategic collaborations or capital infusion give these companies business growth. H...

The micro or small-cap end of the share market is full of shares that will regularly move rapidly higher or lower in the space of just a few days as sentiment swings around the businesses and a lack of liquidity adds to the volatility.  It...

In this piece of writing, we would discuss the three stocks from healthcare sector traded on the ASX. The Australian benchmark index S&P/ASX 200 closed at 6793.4, down by 24.60 points or 0.4% from the previous close, on 26 July 2019. Ov...

The stocks that trade for less than $1 per share and have very low market capitalisation are usually referred to the penny stocks. These stocks are generally associated with small companies and are less liquid. However, penny stocks enable...

Biotron (ASX:BIT), the biotech company that skyrocketed 750 per cent in the space of a week after promising clinical trial results, will host a scientific advisory meeting with “internationally-recognised” HIV-1 experts in the coming weeks....

Australian company Biotron (ASX:BIT) has updated shareholders following the release of positive outcomes from the BIT225-009 phase 2 HIV-1 clinical trial.